Meinong Biotech announced that revenue for the first half of 2026 was 328 million yuan, up 38.71% year on year; net profit attributable to shareholders of listed companies was 18.061 million yuan, down 23.23% year on year, and 23.527 million yuan in the first half of 2025; net profit after deducting non-recurring profit and loss was 177.649 million yuan, down 18.66% year on year. As of June 2026, the company has transferred all remaining funds raised to permanently supplement working capital, and completed the relevant special fund raising account procedures.

Zhitongcaijing · 4d ago
Meinong Biotech announced that revenue for the first half of 2026 was 328 million yuan, up 38.71% year on year; net profit attributable to shareholders of listed companies was 18.061 million yuan, down 23.23% year on year, and 23.527 million yuan in the first half of 2025; net profit after deducting non-recurring profit and loss was 177.649 million yuan, down 18.66% year on year. As of June 2026, the company has transferred all remaining funds raised to permanently supplement working capital, and completed the relevant special fund raising account procedures.